Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 56 | ECE2018 | Next issue

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

Card image cap
ECE 2018, 19 - 22 May 2018; Barcelona, Spain

ea0056p476 | Diabetes therapy | ECE2018

Analysis of safety and efficacy of liraglutide compared with dulaglutide in patients with type 2 diabetes mellitus

Frolova Arina , Orlova Marina , Rodionova Tatiana

Background: Was performed an open study in 2 parallel groups to compare the efficacy and safety of dulaglutide and liraglutide in combination with Metformin in patients with type 2 diabetes mellitus.Methods: Thirty-two patients (13 men and 19 women) with type 2 diabetes mellitus with unsatisfactory glycemic control on Metformin monotherapy were examined. The median age was 52 [44; 61] years old, the duration of diabetes was 4.6 [2,5; 9,0] years, median o...

ea0056p477 | Diabetes therapy | ECE2018

A localized painfull rash induced by linagliptin in a patient with type 2 diabetes

Yildiz Ismail , Gen Ramazan , Batmaz Leyla , Sezer Kerem , Akbay Esen , Yuyucu Karabulut Yasemin

Introduction: Although dipeptidyl peptidase-4 (DPP-4) inhibitores are generally safe and are associated with less side effects compared to other oral antidiabetic medications, they could also be associated with some side effects including skin rash. Herein we report the first case of a type 2 diabetes patient who developed a painfull maculopapular rash induced by linagliptin, a widely used DPP-4 inhibitor.Case presentation: A-54-year old female patient w...

ea0056p478 | Diabetes therapy | ECE2018

Preservation of residual β-insulin function in a patient with a type 1 diabetes treated early by fingolimod for multiple sclerosis

Benderradji Hamza , Kwapich Maxime , Bouzaib Samira , Ythier Hubert , Zephir Helene , Leroy Clara

Introduction: Type 1 diabetes (T1D) and multiple sclerosis (MS) are autoimmune diseases with common immunological mechanisms. Type 1 diabetics have an increased risk of MS. The aim of this work is to report a clinical observation of a partial preservation of β-cell function in a type 1 diabetic patient treated early by Fingolimod for MS.Observation: A polyuro-polydipsic syndrome and a weight loss of 10 kg led to the diagnosis of T1D (typing HLA DR4/...

ea0056p479 | Diabetes therapy | ECE2018

Treating depression in insulin dependant diabetics improves glucoregulation

Radojkovic Jana , Ilic Mijailovic Sanja , Sikanic Natasa , Lalic Katarina

Bacground: It is disputable whether negative effects of comorbid depression in patients with type 2 diabetes can be diminished by treatment of depression. The primary aim of this study was to assess whether addition of antidepressants to existing insulin therapy would further improve glycemic control in these patients. A secondary objective was to assess whether such treatment impairs their lipid and inflammatory status.Material/methods: Total of 50 pati...

ea0056p480 | Diabetes therapy | ECE2018

Comparative analisis of multiple daily injection of insulin and continuous subcutaneous insulin infusion regimes in children and adolescents with type 1 DM in Uzbekistan

Gulyamova Khilola , Said Ismailov , Nasiba Alimova , Suleymanova Feruza

Background: Insulin pumps, devices for continuous subcutaneous insulin infusion have become fundamentally new and progressive step in the treatment of diabetes. To date, there has been no experience with the use of insulin pumps in UzbekistanAims and objectives: To evaluate the effectiveness of insulin pump therapy in comparison with the regime of multiple daily injections (MDI) of insulin.Materials and methods: Forty children and ...

ea0056p481 | Diabetes therapy | ECE2018

Perinatal outcomes in Mexican women with mild gestational diabetes mellitus without treatment diagnosed by the international association of diabetes and pregnancy study groups criteria

Martinez Cruz Nayeli , Reyes Munoz Enrique , Soriano Ortega Karla P. , Arce Sanchez Lidia , Ortega Gonzalez Carlos , Torres Herrera Ursula , Espino y Sosa Salvador , Montoya Estrada Aracely

Aims: To compare the risk of adverse perinatal outcomes (APO) between pregnant women with mild gestational diabetes mellitus (GDM) by International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria without treatment versus women without GDM.Methods: A retrospective cohort study. We included pregnant women with prenatal care and delivery at our Institution. Group 1, women with mild GDM defined by one abnormal glucose value according to ...

ea0056p482 | Diabetes therapy | ECE2018

Meta-analysis of clinical efficacy of traditional chinese medicine formula (Simiao Yong’an Decoction) in treatment of diabetic foot meta-analysis of clinical efficacy of traditional chinese medicine formula (Simiao Yong’an Decoction) in treatment of diabetic foot

Huang Suping , Liu Yongjin , Huang Bowei

Objective: To evaluate the efficacy and safety of Traditional Chinese medicine formula (Simiao Yong’an Decoction) in the treatment of Diabetic foot (DF).Methods: A comprehensive retrieval was made in PubMed, EMRS, EMbase, The Cochrane Library, CNKI, WanFang and other databases to collect randomized controlled trials (RCTs) on the treatment of DF with Simiao Yong’an Decoction (from the establishment of databases to Dec 2017). Two reviewers indep...

ea0056p483 | Diabetes therapy | ECE2018

Maculopapular rash developed after initiation of U-300 glargine insulin in a patient with type 1 diabetes mellitus

Topaloglu Omecan , Evren Bahri , Bilgic Mehmet Akif , Kara Mahmut , Sahin Ibrahim

Introduction: U-300 insulin glargine has been used as a concentrated form of glargine. Skin and subcutaneous tissue disorders (eg, rash, pruritus, and urticaria) have been reported with insulin glargine. But to our knowledge, maculopapular rash has not been reported with use of U-300 insulin glargine. We present a patient with type 1 diabetes mellitus(DM) developing maculopapular rash after initiation of U-300 glargine insulin.Case Report: 37 year-old fe...

ea0056p484 | Diabetes therapy | ECE2018

Dapagliflozin after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Munoz-Jimenez Concepcion , Alhambra-Exposito Maria Rosa , Galvez-Moreno Maria Angeles

Objective: To evaluate the efficacy of dapagliflozin for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with tipo 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and dapagliflozin is added. Variables analyzed baseline and at 6 months after treatme...

ea0056p485 | Diabetes therapy | ECE2018

Canagliflozin after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Alhambra-Exposito Maria Rosa , Munoz-Jimenez Concepcion , Galvez-Moreno Maria Angeles

Objective: To evaluate the efficacy of canagliflozin 100 mg for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with type 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and canagliflozin 100 mg is added. Variables analyzed baseline and at 6 months...

ea0056p486 | Diabetes therapy | ECE2018

Inhibitors SGLT2 after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Munoz-Jimenez Concepcion , Alhambra-Exposito Maria Rosa , Galvez-Moreno Maria Angeles

Objetive: The change of treatment of liraglutide 1.8 mg to dapagliflozin or canaglifonzin 100 mg in patients with optimal glycemic control and stabilization weight loss, achieves progression in weight loss and improves the metabolic control of the patient with tipo 2 diabetes (DM-2). Our objective is to evaluate if there are differences in metabolic control and progression of weight loss in patients treated with canagliflozin 100 mg or dapagliflozin.Pati...

ea0056p487 | Diabetes therapy | ECE2018

Second setp in type 2 diabetes, what to choose?

Exposito Maria Rosa Alhambra , Moreno Paloma Moreno , Martin Ana Barrera , Sanchez Inmaculada Prior , Moreno Maria Angeles Galvez

Introduction: In type 2 diabetes the choice of the second drug after metformina is marked by the basic characteristics of the patient.Objetive: To analyze in real clinical practice the effectiveness of different antidiabetics.Material and methods: Observational study including patients with type 2 diabetes, in which we added to metformina different antidiabetics. We revised them 3-6 months from change.Results...

ea0056p488 | Diabetes therapy | ECE2018

Short term adherence with discharge recommendation for insulin treatment among patients with type 2 diabetes

Koren Shlomit , Hemo Orel , Yoshpe Michael , Koren Ronit , Cantrell Dror , Rapoport Micha J.

Background: Basal-Bolus (BB) insulin treatment is increasingly used in uncontrolled diabetes patients during hospitalization and is commonly recommended on their discharge. However, the extent of adherence with this recommendation is unknown.Aim: To determine the short term adherence of type 2 diabetes mellitus (T2DM) patients discharged from internal medicine wards with recommendation for BB insulin treatment.Methods: Prescription...

ea0056p489 | Diabetes therapy | ECE2018

Dulaglutide; effectiveness in a real world population with type 2 diabetes

Linares Lidia Urbon Lopez de , Soto Cristina Crespo

Diabetes is a chronic disease that is often accompanied by multiple comorbidities and health complications such as overweight/obesity. In the late years therapies improving glycemic control while reducing body weight have become a convenient choice to treat diabetes. One of those therapies are GLP 1 receptor agonists. Dulaglutide allows for a once weekly dosing which might improve compliance; moreover its new application device ease the injection. We show the results of HbA1c ...

ea0056p490 | Diabetes therapy | ECE2018

Experience in clinical practice with new long-acting insulins in type 2 diabetes (T2D)

Vega Maria Molina , Garach Araceli Munoz , Fuentes Miguel Damas , Garcia Carmen Hernandez , Perdigones Cristina Diaz , Pareja Isabel Cornejo , Madueno Francisco Tinahones

Introduction: New long-acting insulin analogues (insulin degludec –ID- and insulin glargine 300 U/ml –IG300-) have proved, in clinical trials, that improve metabolic control with lower hypoglycemia rate in T2D.Objective: To assess characteristics of T2D patients who were given ID and IG300 and to evaluate their effect on metabolic control, weight and insulin dose.Material and methods: We studied T2D patients whose treatme...

ea0056p491 | Diabetes therapy | ECE2018

Six months of retrospective glycemic control and anthropometric outcomes in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data from single center

Cander Soner , Calapkulu Murat , Gul Ozen Oz , Ersoy Canan

Introduction: SGLT2 inhibitors have been an important step in the treatment of diabetes. With numerous controlled experimental studies of these antidiabetic drugs, evaluation of real-life data after entry into clinical practice is an important condition. In our study, it was aimed to evaluate short-term results on glycemic control and weight loss in a narrow group of patients in the single tertiary medical center.Methods: The study was retrospectively de...

ea0056p492 | Diabetes therapy | ECE2018

Can patient profile influence on GLP1 analogues prescription among physicians?: patient selection and perspectives

Cayon-Blanco Manuel , Garcia-Figueras-Mateos Carolina

Introduction: The use of glucagon like peptide 1 analogues (GLP1a) for the treatment of type 2 diabetes mellitus (T2DM) is growing. After a decade-long effort to improve the pharmacokinetics of GLP1, a number of GLP1a are currently available on the market. With a view to identifying patient characteristics that could influence physicians’ prescription of different GLP1a we carried out this observational study in routine clinical practice conditions. Outcomes after add-on ...

ea0056p493 | Diabetes therapy | ECE2018

SGLT-2 inhibitors or GLP-1 receptor agonists as add-on to insulin therapy in patients with type 2 diabetes: comparative analysis

Garcia-Figueras-Mateos Carolina , Cayon-Blanco Manuel

Introduction: Multiple studies have evaluated the efficacy of SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1ra) in patients with type 2 diabetes mellitus (T2DM). However, their efficacy in clinical practice is less known in patients receiving insulin and few are the studies that compare use of SGLT2i vs GLP1ra as add-on therapy to insulin. This study aims to assess clinical efficacy of both treatments in a cohort of patients with T2DM on insulin and poor glycemic...

ea0056p494 | Diabetes therapy | ECE2018

Clinical predictors of therapeutic response to SGLT-2 inhibitors

Garcia-Figueras-Mateos Carolina , Cayon-Blanco Manuel

Introduction: Predictors for therapeutical response of SGLT-2 inhibitors (SGLT2i) is scarcely studied. The aim of the study was to retrospectively analyse the clinical parameters that contribute to the therapeutic outcomes of SGLT2i.Methods/design: We enrolled 75 patients with type 2 diabetes mellitus (T2DM), treated with SGLT2i for longer than three months. The patients were divided into two groups: good responders (if HbA1c-lowering effects were &#8805...

ea0056p495 | Diabetes therapy | ECE2018

Improvement control rate of blood glucose/blood pressure/blood lipid in diabetes patients by hospital-community integrated management in Shanghai

Wei Li , Zeng Yuanyuan , Zhu Chaoyu , Xiao Yuanyuan , Gao Qingge

Background: Diabetes prevalence and mortality are increasing rapidly and glycemic goals (hemoglobin A1c < 7%) are often not achieved in patients with type 2 diabetes in China, The low control rate of diabetes has become a global problem. The management of community diabetes is the most effective choice to prevent and control chronic diseases.Objective: To improve the management of diabetes mellitus in community, we analyze the effect of hospital-comm...

ea0056p496 | Diabetes therapy | ECE2018

Abstract withdrawn....

ea0056p497 | Diabetes therapy | ECE2018

A case with metformin overdose associated acidosis

Yilmaz Merve , Karatas Adnan , Kehribar Demet Yalcin

Introduction: Metformin-induced lactic acidosis (MALA) is one of the most important drug toxicities with high morbidity and mortality rates. Nonspecific symptoms such as nausea, vomiting, epigastric pain, hypotension, tachycardia, tachypnea, arrhythmia, renal insufficiency, coma and cardiac arrest can be seen. Here we are presenting a case with acidosis due to metformin overdose.Case: A 36-year-old female patient with a history of type 2 diabetes for thr...

ea0056p498 | Diabetes therapy | ECE2018

Cognitive status, anxiety and depression in patients with type 2 diabetes mellitus on selective DPP4 inhibitor therapy

Djurovic Marina Nikolic , Jemuovic Zvezdana , Vasovic Olga , Pekic Sandra , Miljic Dragana , Stojanovic Marko , Djokic Biljana Salak , Krljanac Gordana , Petakov Milan

Introduction: Cognitive functions and mood (anxiety and depression) are often impaired in diabetes mellitus (DM). Dipeptidyl peptidase-4 inhibitor (DPP-4) has been shown to exert beneficial effects on insulin sensitivity and glycoregulation in T2DM patients. Introducing DPP-4 therapy leads to maintaining control of glucose levels which could ameliorate or slow down further cognitive and mood disorders impairment.Aim: To evaluate influence of selective DP...

ea0056p499 | Diabetes therapy | ECE2018

Metabolic effects of liraglutide in type 2 diabetic patients.

Muros Mariola Mendez , Portillo Cristobal Morales , Hermosilla Antonio Manuel Garrido , Septimo Vianney Magaly Santiago , Perez Antonio Perez , Margalet Victor Sanchez , Brocca Maria Asuncion Martinez

Objectives: Obesity and type 2 diabetes mellitus (DM2) are risk factors for non-alcoholic fatty liver disease (NAFLD). The main objective was to study the incidence of NAFLD using the Hepatic Steatosis Index (HSI) in obese patients with DM2. Secondary objectives were to analyse the effect of liraglutide over HSI, body mass index (BMI) and glycated hemoglobin (HbA1c).Methods: Retrospective observational study of obese type 2 diabetic patients treated with...

ea0056p500 | Diabetes therapy | ECE2018

Efficacy of glucose control on a combination of dapagliflozin in people with type 2 diabetes mellitus in Korea

Kim Chong Hwa , Mok Ji Oh , Lee Ki Young , Kim Sung Rae

Objective: Dapagliflozin, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, reduces hyperglycemia and body weight by inhibiting renal glucose reabsorption. However, only a few studies have shown the glycemic efficacy on a combination of dapagliflozin in type 2 diabetic patients in Korean. We evaluated the efficacy and safety of glucose control on a combination of dapagliflozin in people with type 2 diabetes in Korea.Methods: This is a retrospective, obs...

ea0056p501 | Diabetes therapy | ECE2018

Comparison of occurrence of fasting hyperinsulinemia according to type of insulin analogs

Ahn Kyu Jeung , Kang Hyoseok , Cho In-Jin , Hwang You-Cheol , Jeong In-Kyung , Chung Ho-Yeon

Background: A variety of insulin analogs have been developed and used for the treatment of diabetes mellitus. We often experience elevated serum insulin levels when insulin analog is used, and thus have difficulty in assessing insulin resistance and secretion using serum insulin results. This study aimed to investigate the differences in serum fasting insulin level and insulin antibodies according to the type of insulin analogs.Method: We conducted a ret...

ea0056p502 | Diabetes therapy | ECE2018

The impact of different glucose-lowering regimens on cardiovascular disease in type 2 diabetes

Vujosevic Snezana , Agic Selim , Borozan Sanja , Vucetic Sanja , Kavaric Sreten , Boskovic Olivera , Djogo Aleksandar , Krnjevic Djordjije , Muzurovic Emir , Madzgalj Dragomir

Introduction: American Heart Association considers diabetes mellitus (DM) to be one of seven major controllable risk factors for cardiovascular disease. At least 68% of patients age 65 or older with DM die from some form of heart disease while 16% die as a consequence of stroke. Studies conducted in patients with type 2 DM (T2DM) have not confirmed a significant association between a certain types of glucose-lowering drugs and a presence of cardiovascular events.<p class="...

ea0056p503 | Diabetes therapy | ECE2018

Evaluation of the risk of hypoglycemias using a questionnaire in patients with type 2 diabetes

Arevalo Mayra Velasquez , Servat Olga Simo , Hernandez Cristina , Romero Diana , Creus Carme , Ciudin Andreea , Mesa Jordi , Simo Rafael

Introduction: The available questionnaires for the detection of hypoglycemia are designed for patients with type 1 Diabetes (T1DM), and do not take into account some characteristics of patients with type 2 Diabetes (T2DM). For instance most of T2DM patients do not perform capillary blood glucose self-monitoring as part of their daily treatment and hypoglycemia might be underestimated. Nevertheless, hypoglycemia can have a negative impact on T2DM patients, in terms of increasin...

ea0056p504 | Diabetes therapy | ECE2018

The intensity of metabolic processes due to different variants of polymorphism rs1801282 Pro12Ala of the PPARG gene in patients with diabetes mellitus type 2

Valeeva Farida , Ahmetov Ildus , Kiseleva Tatyana , Khasanova Kamilya , Izmailova Maria , Valeeva Elena

Aim: To investigate the effect of the standard dietary recommendations in diabetes mellitus type 2 to the intensity of metabolic processes due to different variants of polymorphism rs1801282 Pro12Ala of the PPARG gene.Materials and methods: 37 patients (11 men and 26 women) in the age of 38–76 years old (the mean age 56.8±9.55 y.o.), with the verified diagnosis of diabetes mellitus type 2 (the mean duration of illness 5.7±3.59 years) and t...

ea0056p505 | Diabetes therapy | ECE2018

A latent autoimmune diabetes in adults (LADA) case renamed after six years of diabetes diagnosis when complicated with diabetic ketoacidosis induced by dapagliflozin

Ekiz-Bilir Betul , Bilir Bulent , Elbuken Gulsah

Introduction: LADA (Latent autoimmune diabetes in adults) is an adult-onset and more indolent variety of autoimmune type 1 diabetes mellitus. In autoimmune diabetes, younger individuals typically have a rapid rate of beta-cell destruction and usually present with ketoacidosis, while adults often maintain sufficient insulin secretion to prevent ketoacidosis for many years. LADA is usually misdiagnosed initially as type 2 diabetes due to its late onset but LADA patients are anti...

ea0056p506 | Diabetes therapy | ECE2018

Awareness of patients with diabetes on the disease

Kraskovskaya Alexandra , Shyshko Olga , Sazonava Alens

Relevance: Patients with diabetes are not always sufficiently informed about disease, approaches to its treatment, and the need to prevent complications.Purpose: To evaluate the awareness of patients about diabetes in inpatient and outpatient settings.Materials and methods: Participation in the study was accepted by patients with 1 and 2 types of diabetes in inpatient and outpatient settings. The questionnaire consisted of alternat...

ea0056p507 | Diabetes therapy | ECE2018

Efficacy in metabolic control and weight loss of combined treatment with GLP-1 receptor analogues and SGLT-2 inhibitors

Damas-Fuentes Miguel , Munoz-Garach Araceli , Maraver-Selfa Silvia , Molina-Vega Maria , Hernandez-Garcia Carmen , Diaz-Perdigones Cristina , Tinahones-Madueno Francisco

Introduction: The emergence of a new generation of antidiabetic drugs (GLP-1RA and SGLT-2i) with complementary mechanisms of action offer new alternatives in the treatment of patients with T2D and poor metabolic control.Objectives: To evaluate the efficacy of the aGLP-1 and iSGLT2 combination on metabolic control, weight, blood pressure and insulin dose in patients with DM2.Methods: Observational, retrospective study. We studied T2...

ea0056p508 | Diabetes therapy | ECE2018

Insulin requirements and obstetric outcomes in pregnant woment with type 1 diabetes under continuous subcutaneous insulin infusion (CSII)

Diez Lura Chinchurreta , Garcia Marta , Goni Maria Jose , Irigaray Ana , Terreros Amaia Sain de los , Eguilaz Nerea , Forga Lluis

Objectives: The gestations in patients with type 1 diabetes are associated with an increase in maternal-fetal complications. Adequate glycemic control during pregnancy has been shown to reduce adverse events. Given that, the treatment with insulin pump improves glycemic control and that pregnancy implies constant changes in insulin resistance, our objective is to analyze the changes in insulin requirements in pregnant patients under CSII.Materials and me...

ea0056p509 | Diabetes therapy | ECE2018

Addition of sodium-glucose co-transporter type 2 inhibitors to diabetic patients type 2 in treatment with glucagon-like peptide-1 agonists: clinical results

Laguna Ma del Carmen Serrano , Ponce Maria Hayon , Martinez David Blanquez , Perez Maria Dolores Aviles , Vela Elena Torres

Background: The complex involvement of multiple metabolic defects in the pathogenesis of type 2 diabetes mellitus (T2DM) makes difficult the treatment in monotherapy, therefore, the use of different antidiabetic drugs with different and complementary mechanisms of action could result in better glycemic control with favorable metabolic changes.Objective: To determine the effectiveness and safety of the addition of a sodium-glucose co-transporter type 2 in...

ea0056p510 | Diabetes therapy | ECE2018

Psychopathological determinants of enhanced quality of life in continuous subcutaneous insulin infusion therapy

Pereira Miguel , Goncalves Ana , Neves Celestino , Oliveira Sofia , Esteves Cesar , Arteiro Cristina , Costa Anabela , Redondo Carmo , Carvalho Davide

Introduction: Scientific progress allowed an evolution on the therapeutic of diabetes mellitus. Continuous subcutaneous insulin infusion therapy (CSII) is one good example, but, beside patients motivation little is known about other psychological factors of success in this therapeutic and how they contribute to quality of life (QoL).Objectives: Determining some psychopathological predictors of CSII satisfaction and QoL improvement in patients on CSII the...

ea0056p511 | Diabetes therapy | ECE2018

Effects of opuntia ficus-indica plant extract ingestion on glucose and insulin plasma levels during oral glucose tolerance test

Christou Maria , Markozannes Georgios , Tigas Stelios

Background: Cladodes of the nopal opuntia streptacantha (prickly-pear cactus) have been traditionally used for the treatment of diabetes in Mexico. Limited data from studies in experimental animals and humans with prediabetes or type 2 diabetes (DM2), have shown promising antihyperglycemic effects using plant extracts of the streptacantha and ficus-indica opuntia species. The purpose of this study was to assess the effect of opuntia ficus-indica<...

ea0056p512 | Diabetes therapy | ECE2018

Predictive factors of starting insulin in gestational diabetes’ Management: About 191 cases

Driouich Yasmine , El Aziz Siham , Bensbaa Salma , Chadli Asma

Introduction: Gestational diabetes’ (GDM) intensive management of with adequate insulin therapy prevents maternal, fetal and neonatal complications associated with hyperglycaemia.Objective: Identify predictive factors for starting insulin in gestational diabetes’ management.Methods: We report a retrospective study conducted from January 2010 to December 2016, involving 191 patients followed in the Endocrinology - Diabetol...

ea0056p513 | Diabetes therapy | ECE2018

Safety and efficacy of different insulin regimens in treatment of type 2 diabetic patients who insist to fast during Ramadan 1437 (Hijri) In Fayoum Governorate, Egypt

Mashahit Mohamed A , Ahmed Abd El Aal Riham , Ezzat Eman M , Zaki Othman

Background: Fasting during Ramadan is an obligatory duty for all healthy adult Muslims. However, a lot of type 2 diabetic Muslim patients insist on fasting whatever their condition. There are several potential physiological benefits from fasting, but the prolonged fasting hours during summer provides many questions about safety and efficacy of different insulin regimens for treatment of type 2 diabetic patients during Ramadan. So we aimed in this study is to assess safety and ...

ea0056p514 | Diabetes therapy | ECE2018

Pregnancy and diabetes: an overview about 144 patients

Khalil Ikram , El Aziz Siham , Bensbaa Salma , Chadli Asmaa

Introduction: Diabetic pregnancy is a high-risk pregnancy requiring a multidisciplinary approach and close monitoring to prevent maternal-fetal complications. Our study objective was to determine the diabetic pregnancies outcome of in order to improve their management.Patients and methods: A descriptive retrospective study including 144 patients with diabetic pregnancy followed at the Endocrinology-Diabetology service between January 2016 and September 2...

ea0056p515 | Diabetes therapy | ECE2018

Moroccan woman pregnant diabetic: what dietary errors? About 60 cases

Khalil Ikram , Aziz Siham El , Bensbaa Salma , Chadli Asmaa

Introduction: Diet plays an important role in glycemic control in diabetic pregnant women.Study objectives: To determine the major dietary errors in pregnant women with diabetes.Patients and methods: A descriptive retrospective study including 60 patients with diabetic pregnancy hospitalized in Endocrinology and Diabetology service between January to December 2016. Data collection was done from medical records.The statistical analy...

ea0056p516 | Diabetes therapy | ECE2018

The flexible insulin therapy: satisfaction after the change of treatment? About 73 cases

Boulbaroud Zineb , Aziz Siham El , Chadli Asma

Introduction: The Flexible Insulin therapy (FIT) is considered as the therapeutic reference of type 1 Diabetes mellitus. FIT Improves diabetic patient’s quality of life with a great benefit, through food flexibility while providing optimal glycemic control with reduced incidence of both acute and chronic complications. The aim of the study was to evaluate satisfaction on changing treatment as a result of education FIT.Methods: Prospecti...

ea0056p517 | Diabetes therapy | ECE2018

Long-term results of continuous subcutaneous insulin infusion on glycemic control and severe hypoglycemias

do Vale Sonia , Carvalho Raquel , Matos Tania , Costa Cristiana , Filipa Martins Ana , Silvestre Catarina , Joao Bugalho Maria

Introduction: The use of Continuous Subcutaneous Insulin Infusion (CSII) is expected to improve glycemic control and to reduce hypoglycemia events. However, long-term beneficial results in glucose control are not always observed. We evaluated long-time glucose control and severe hypoglycemias in type 1 diabetic patients using CSII, without continuous glucose monitoring.Patients and methods: This was a retrospective study of adult type 1 diabetic patients...

ea0056p518 | Diabetes therapy | ECE2018

The anxiety and depression disorders in the diabetic type 1 (preliminary results)

Kibhat Lygie , El Aziz Siham , Bensbaa Salma , Chadli Asma

Introduction: The relationship between diabetes and anxiety and depression is bidirectional. Patients with somatic disorders such as diabetes present on average twice more psychiatric disorders than the general population. The aim of our study was to identify the level of anxiety and depression in people with diabetes type 1 and to assess their impact on the clinical features of the disease.Patients and methods: We conducted a transversal descriptive stu...